Headlines about EXACT Sciences (NASDAQ:EXAS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. EXACT Sciences earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.4852565616824 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
- Trader Alert: Unusual Volume Spotted in Exact Sciences Corporation (NASDAQ:EXAS) (nismagazine.com)
- Today’s Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences Corporation (finance.yahoo.com)
- Exact Sciences Announces Offering of $500 Million Convertible Senior Notes Due 2025 (finance.yahoo.com)
- EXACT Sciences (EXAS) Rating Reiterated by William Blair (americanbankingnews.com)
- 3 Slides That Paint a Great Picture for Exact Sciences' Future (finance.yahoo.com)
EXACT Sciences (NASDAQ:EXAS) traded down $2.44 during trading hours on Monday, reaching $52.62. The company had a trading volume of 6,302,800 shares, compared to its average volume of 2,130,000. The firm has a market capitalization of $6,300.00, a price-to-earnings ratio of -45.76 and a beta of 0.68. EXACT Sciences has a 1 year low of $16.95 and a 1 year high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.
Several equities research analysts have weighed in on the company. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, January 10th. Jefferies Group raised their price target on EXACT Sciences to $60.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Robert W. Baird raised their price target on EXACT Sciences from $49.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. Benchmark reissued a “buy” rating and set a $60.00 price target (up from $50.00) on shares of EXACT Sciences in a report on Tuesday, October 31st. Finally, Bank of America raised their price target on EXACT Sciences from $56.00 to $58.00 and gave the company a “buy” rating in a report on Tuesday, October 31st. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. EXACT Sciences has a consensus rating of “Buy” and an average price target of $50.58.
In related news, SVP D Scott Coward sold 1,665 shares of EXACT Sciences stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total transaction of $87,479.10. Following the transaction, the senior vice president now directly owns 37,558 shares of the company’s stock, valued at $1,973,297.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 134,057 shares of EXACT Sciences stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $59.50, for a total value of $7,976,391.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 610,433 shares of company stock worth $34,341,306. 4.00% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/01/15/exact-sciences-exas-earning-somewhat-positive-news-coverage-study-shows.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
What are top analysts saying about EXACT Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for EXACT Sciences and related companies.